title: Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.
abstract: BACKGROUND
  In Japan, patients with hepatitis C virus (HCV)-associated liver disease are getting older, and thus the number of deaths due to such disease is increasing. The efficacy of combination therapy with ribavirin and interferon for chronic HCV infection in elderly patients has not been fully clarified. The aim of the present study was to evaluate the efficacy and tolerability of combination therapy in such patients.
  
  
  METHODS
  Two hundred and twenty consecutive patients with chronic hepatitis C were treated with combination therapy. These patients were divided into two groups according to age: patients >or= 60 years (n = 66) and patients < 60 years (n = 154). Clinical characteristics, the sustained virologic response (SVR) rate obtained by intention-to-treat analysis, and the rate of reduction or discontinuation of ribavirin were compared between the two groups.
  
  
  RESULTS
  The ribavirin discontinuation rate was significantly higher in the patients aged >or=60 years than in the patients aged <60 years. However, the SVR rates did not differ significantly between patients aged >or=60 years and those aged <60 years (31.8% vs 38.3% by intention-to-treat analysis). According to multivariate analysis, genotype and HCV viral load were significantly associated with SVR while patient age did not affect SVR.
  
  
  CONCLUSIONS
  Treatment of chronic hepatitis C with combination therapy was comparably effective between patients aged >or=60 years and those aged <60 years, although the ribavirin discontinuation rate was higher among the older patients than the younger patients.
authors.affiliation: Department of Gastroenterology, Nagoya University School of Medicine, Showa-ku, Nagoya, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Honda
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Katano
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Urano
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Murayama
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Hayashi
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Ishigami
authors.forename: Isao
authors.initials: I
authors.lastname: Nakano
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yoshioka
authors.forename: Hidenori
authors.initials: H
authors.lastname: Toyoda
authors.forename: Takashi
authors.initials: T
authors.lastname: Kumada
authors.forename: Hidemi
authors.initials: H
authors.lastname: Goto
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin